B3GNT2 and neoplasm: Upregulation of B3GNT2, which encodes a poly-N-acetyllactosamine synthase, allows human melanoma cells to evade T cell killing in different cancer cell types, and can reduce T cell activation and disrupt the interaction between tumor and T cells (Joung et al., 2022).